Last Posted: Mar-03-2017 8AM
From Tier Table Database
CDC Office of Public Health Genomics (OPHG) conducts horizon scanning (a systematic research method to find and follow novel technologies appearing in the literature) to identify and track the progress of genomic tests as they move from research into clinical and public health practice. As an aid in organizing horizon scanning results, OPHG ranks genomic tests, and family health history applications, by levels of evidence. See detail.
| Disease/Disorder | Test to be Assessed | Intended Use | Tier Classified | Detail |
|---|---|---|---|---|
| Metastatic colorectal cancer | NRAS or PIK3CA mutation analysis and/or testing for loss of PTEN or AKT protein expression | Pharmacogenomic for anti-EGFR therapy | Tier 3  | |
| Dukes’ C colon cancer, metastatic colorectal cancer, metastatic breast cancer | DPD testing | Pharmacogenomic for 5-FU (capecitabine) | Tier 2 | |
| Colorectal cancer in patient with relatives (two or more first- or second-degree) with Lynch syndrome related cancer at any age | Testing for Lynch syndrome | Diagnostic, screening | Tier 2 | |
| Colorectal cancer in patient with relative (one or more first-degree) with Lynch syndrome related cancer that was diagnosed under age 50 years | Testing for Lynch syndrome | Diagnostic, screening | Tier 2 | |
| MSI-H histology in colorectal cancer patients younger than 60 years | Testing for Lynch syndrome | Diagnostic, screening | Tier 2 |
.png)
No hay comentarios:
Publicar un comentario